Once Daily Trospium Chloride is Effective and Well Tolerated for the Treatment of Overactive Bladder: Results From a Multicenter Phase III Trial

Journal of Urology

Volumn 178, Issue 3, 2007, Pages 978-984

  Staskin, David ^a   Sand, Peter ^b   Zinner, Norman ^c   Dmochowski, Roger ^d  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Western Clinical Research   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

overactive; trospium chloride; urinary bladder; urinary incontinence

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CALCIUM; MULTIVITAMIN; PLACEBO; TROSPIUM CHLORIDE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ANTICHOLINERGIC SYNDROME; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DRY SKIN; DYSPEPSIA; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; LABORATORY TEST; LOWER ABDOMINAL PAIN; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; NAUSEA; OVERACTIVE BLADDER; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION; XEROSTOMIA;

DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NORTROPANES; PARASYMPATHOLYTICS; URINARY BLADDER, OVERACTIVE; URINATION;

EID: 34547679417     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.05.058     Document Type: Article

References (20)

1. Rudy D., Cline K., Harris R., Goldberg K., and Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 67 (2006) 275
2. Zinner N., Gittelman M., Harris R., Susset J., Kanelos A., and Auerbach S. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 171 (2004) 2311
3. Beckmann-Knopp S., Rietbrock S., Weyhenmeyer R., Bocker R.H., Beckurts K.T., and Lang W. Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes. Pharmacol Toxicol 85 (1999) 299
4. Doroshyenko O., Jetter A., Odenthal K.P., and Fuhr U. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet 44 (2005) 701
5. Ditropan® XL (Oxybutynin Chloride) Prescribing Information (2004). http://www.ditropanxl.com/active/janus/en_US/assets/common/company/pi/ditropanxl.pdf Available at http://www.ditropanxl.com/active/janus/en_US/assets/common/company/pi/ditropanxl.pdf. Accessed January 24, 2007
6. Detrol® LA (Tolterodine Tartrate) Prescribing Information (2005). http://pfizer.com/pfizer/download/uspi_detrol_la.pdf Available at http://pfizer.com/pfizer/download/uspi_detrol_la.pdf. Accessed January 24, 2007
7. VESIcare® (Solifenacin Succinate) Prescribing Information (2004). http://www.vesicare.com/assets/vesicare_prescribing_info.pdf Available at http://www.vesicare.com/assets/vesicare_prescribing_info.pdf. Accessed January 24, 2007
8. Enablex® (Darifenacin) Prescribing Information (2006). http://www.enablex.com/content/prescribing.jsp Available at http://www.enablex.com/content/prescribing.jsp. Accessed January 24, 2007
9. Scheife R., and Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 27 (2005) 144
10. Staskin D.R., and Harnett M.D. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Sci 5 (2004) 423
11. Kim Y.T., Yoshimura N., Masuda H., de Miguel F., and Chancellor M.B. Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU Int 97 (2006) 400
12. Rudy D., Cline K., Harris R., Goldberg K., and Dmochowski R. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU Int 97 (2006) 540
13. Silver N., Sandage B., Sabounjian L., Schwiderski U., and Harnett M. A comparison of the pharmacokinetics of once-daily trospium chloride extended-release 60 mg in fasted, fasted with antacid, and high-fat meal conditions (2007) Presented at winter meeting of Society for Urodynamics and Female Urology, San Diego, California, February 21-24
14. Appell R.A., Chancellor M.B., Zobrist R.H., Thomas H., and Sanders S.W. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 78 (2003) 696
15. Van Kerrebroeck P., Kreder K., Jonas U., Zinner N., and Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 57 (2001) 414
16. Nixon A., Colman S., Sabounjian L., Sandage B., Schwiderski U.E., Staskin D.R., et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 174 (2005) 604
17. Zinner N., Harnett M., Sabounjian L., Sandage B., Dmochowski R., and Staskin D. The overactive bladder-symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder. J Urol 173 (2005) 1639
18. Starkman J.S., and Dmochowski R.R. Management of overactive bladder with transdermal oxybutynin. Rev Urol 8 (2006) 93
19. Olsson B., and Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet 40 (2001) 227
20. Sanctura® (Trospium) Prescribing Information (2006). http://www.sanctura.com/pdf/sanctura_pi.pdf Available at http://www.sanctura.com/pdf/sanctura_pi.pdf. Accessed March 9, 2007